The treatment is a nasal spray form of Ketamine recently approved by the FDA known as Esketamine ... show an average ...

Called Spravato, a brand name for esketamine, and developed by Johnson & Johnson, the drug is a nasal spray designed to treat severe forms of depression that don't respond to other medications.

Major depressive disorder (MDD) affects approximately 280 million people globally and is one of the leading causes of ...

Treatment with esketamine combined with an SNRI is linked to fewer adverse outcomes than treatment with an SSRI alone.

Esketamine, a nasal spray formulation of the S-enantiomer of ketamine, offers a novel mechanism of action, providing rapid relief for patients who have not responded to traditional antidepressants.